NCCTG N9831 May 2005 Update
Targeted Adjuvant Systemic Therapy of Breast Cancer
Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel +/- Trastuzumab as Adjuvant
Clinical Research Goals
Study Schema
Eligibility
Clinical Endpoints
Statistical Plan Addition of H to AC -> T
Statistical Plan Timing of H Initiation
Cardiac Testing
Impact of Joint Analysis on N9831 (April 2005)
Patient/Event Status at Time of Joint Analysis (April 2005)
Patient and Tumor Characteristics
Results Disease-Free Survival
Disease-Free Survival: A vs C From the Joint Analysis
Disease-Free Survival: A vs B N9831
Disease-Free Survival: B vs C N9831
Overall Survival
Other Relevant Factors for Patient Management
HER2 Testing in N9831
Cardiac Monitoring Plan
Effect of the Introduction of H on Cardiac Tolerability
Effect of Introduction of Traztusumab on Disease Recurrence
N9831 -- Future Plans
NCCTG N9831 Collaborative Team
Peter A Kaufman, MD